Dec 10 (Reuters) - Astria Therapeutics ATXS.O:
ASTRIA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR STAR-0310, A MONOCLONAL ANTIBODY OX40 ANTAGONIST FOR THE TREATMENT OF ATOPIC DERMATITIS
ASTRIA THERAPEUTICS INC: PHASE 1A TRIAL OF STAR-0310 IN HEALTHY VOLUNTEERS EXPECTED TO INITIATE IN Q1 2025
ASTRIA THERAPEUTICS INC: EARLY PROOF-OF-CONCEPT RESULTS EXPECTED IN Q3 2025
Source text: ID:nBw3gg0WFa
Further company coverage: ATXS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.